Received Feb 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 33G3M | — |
administered with a second dose on January 16th 2025; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 39-year-old female patient who received Flu Seasonal TIV Quebec (FluLaval 2024-2025 season) (batch number 33G3M, expiry date 30-JUN-2025) for prophylaxis. Previously administered products included Flulaval (received 1st dose on 8th October 2024, batch number 33G3M, expiry date 30th June 2025.). On 16-JAN-2025, the patient received the 2nd dose of FluLaval 2024-2025 season. On 16-JAN-2025, an unknown time after receiving FluLaval 2024-2025 season, the patient experienced extra dose administered (Verbatim: administered with a second dose on January 16th 2025). The outcome of the extra dose administered was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 16-JAN-2025 Nurse mentioned that a patient who received a prior dose of FluLaval back on October 8th 2024 was administered with a second dose on January 16th 2025 which led to Extra dose administered. Lot number and expiration date were the same for both doses.